Hormonal
Somatotypes (ectomorph, mesomorph, endomorph) correspond to distinct metabolic and hormonal profiles that influence individual responses to diet and exercise, suggesting tailored interventions are more effective.
Understand your body type as a starting point for tailoring your approach. Ectomorphs may need high-protein and resistance training to preserve muscle. Mesomorphs may respond well to balanced macronutrients and strength training. Endomorphs may benefit from low-GI diets and stress management to modulate insulin and cortisol. Use this framework to personalize your strategy.
The classification of somatotypes—ectomorph, mesomorph, and endomorph—provides an essential framework for understanding individual variability in weight management. While initially based on external physique, these body types correspond to distinct metabolic and physiological profiles that influence each person’s response to diet, exercise, and caloric changes.
Why this rating
The paper presents this as a framework supported by cited literature, but it is a narrative review.
Source
Beyond Calories: Individual Metabolic and Hormonal Adaptations Driving Variability in Weight Management—A State-of-the-Art Narrative Review
Nikolaos Theodorakis et al. · International Journal of Molecular Sciences · 2024
DOI 10.3390/ijms252413438
More from this paper
- Caloric restriction triggers adaptive thermogenesis, including reduced BMR/RMR, hormonal shifts (lowered T3, leptin, increased ghrelin), and increased appetite, which persist long-term and contribute to weight regain.Good
- Individual metabolic and hormonal adaptations, including somatotype-specific responses and adaptive thermogenesis, drive significant variability in weight management outcomes, rendering the 'calories in, calories out' model insufficient for personalized strategies.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →